LLY

858

+1.28%↑

UNH

565.37

+0.22%↑

NVO

131.55

+1.32%↑

JNJ

154.58

-0.46%↓

MRK

125.76

+1.19%↑

LLY

858

+1.28%↑

UNH

565.37

+0.22%↑

NVO

131.55

+1.32%↑

JNJ

154.58

-0.46%↓

MRK

125.76

+1.19%↑

LLY

858

+1.28%↑

UNH

565.37

+0.22%↑

NVO

131.55

+1.32%↑

JNJ

154.58

-0.46%↓

MRK

125.76

+1.19%↑

LLY

858

+1.28%↑

UNH

565.37

+0.22%↑

NVO

131.55

+1.32%↑

JNJ

154.58

-0.46%↓

MRK

125.76

+1.19%↑

LLY

858

+1.28%↑

UNH

565.37

+0.22%↑

NVO

131.55

+1.32%↑

JNJ

154.58

-0.46%↓

MRK

125.76

+1.19%↑

Search

Abbott Laboratories

Suletud

Sektor Tervishoid

101.92 1.97

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

101.83

Max

102.39

Põhinäitajad

By Trading Economics

Sissetulek

-369M

1.2B

Müük

-281M

10B

P/E

Sektori keskmine

34.87

79.786

Aktsiakasum

0.98

Kasumimarginaal

12.299

Töötajad

114,000

EBITDA

-28M

2.4B

Soovitused

By TipRanks

Soovitused

Tugev "osta" hinnang

12 kuu keskmine prognoos

+26.21 upside

Dividendid

By Dow Jones

Järgmine tulemuste avaldamine

16. okt 2024

Järgmine dividendimakse kuupäev

15. aug 2024

Järgmine aktsia dividendi kuupäev (ex-date)

10. okt 2024

Turustatistika

By TradingEconomics

Turukapital

-555M

179B

Eelmine avamishind

99.95

Eelmine sulgemishind

101.92

Uudiste sentiment

By Acuity

45%

55%

107 / 369 Pingereas Healthcare

Tehniline skoor

By Trading Central

Kindlus

Very Strong Bearish Evidence

Abbott Laboratories Graafik

Seotud uudised

18. juuli 2024, 12:21 UTC

Tulu

Abbott Labs Lifts FY24 Outlook After 2Q Sales Rise

18. juuli 2024, 19:04 UTC

Market Talk
Tulu

Abbott CEO Warns of Health Crisis if Preterm Formula Pulled -- Market Talk

18. juuli 2024, 11:43 UTC

Tulu

Abbott Laboratories Earnings Top Views, Full-Year Guidance Raised -- IBD

18. juuli 2024, 11:34 UTC

Tulu

Abbott Labs Sees 3Q Adj EPS $1.18-Adj EPS $1.22 >ABT

18. juuli 2024, 11:34 UTC

Tulu

Abbott Labs Sees 3Q EPS 85c-EPS 89c >ABT

18. juuli 2024, 11:31 UTC

Tulu

Abbott Labs Narrows FY24 Organic Sales Growth View, Ex-COVID-19 Testing-Related Sales, to 9.5% to 10% >ABT

18. juuli 2024, 11:30 UTC

Tulu

Abbott Labs Sees FY Adj EPS $4.61-Adj EPS $4.71 >ABT

18. juuli 2024, 11:30 UTC

Tulu

Abbott Labs Sees FY EPS $3.30-EPS $3.40 >ABT

18. juuli 2024, 11:30 UTC

Tulu

Abbott Labs 2Q Organic Sales Growth Up 7.4% >ABT

18. juuli 2024, 11:30 UTC

Tulu

Abbott Labs 2Q Sales $10.38B >ABT

18. juuli 2024, 11:30 UTC

Tulu

Abbott Labs 2Q Adj EPS $1.14 >ABT

18. juuli 2024, 11:30 UTC

Tulu

Abbott Labs 2Q Net $1.3B >ABT

18. juuli 2024, 11:30 UTC

Tulu

Abbott Labs 2Q EPS 74c >ABT

18. juuli 2024, 11:30 UTC

Tulu

Abbott Raises Full-Yr Guidance

14. juuli 2024, 22:41 UTC

Tulu

Stocks Poised for Higher Open -- Barrons.com

12. juuli 2024, 23:29 UTC

Omandamised, ülevõtmised, äriostud

BP Says Oil Demand Is Falling, While OPEC Says It's Rising. What Gives? -- Barrons.com

17. apr 2024, 13:54 UTC

Tulu

Abbott Labs Stock Is Slipping After Earnings Beat. Here's Why. -- Barrons.com

17. apr 2024, 12:41 UTC

Peamised uudised
Tulu

Abbott Labs Stock Is Slipping. Disappointing Guidance Trumps a Strong Quarter. -- Barrons.com

17. apr 2024, 11:52 UTC

Tulu

Abbott Labs Jumps, Retreats On Q1 Beat, Shy Guidance -- IBD

17. apr 2024, 11:45 UTC

Tulu

Abbott Labs First-Quarter Results Top Estimates Amid Strong Medical Device Sales -- MarketWatch

17. apr 2024, 11:32 UTC

Tulu

Abbott Labs Narrows 2024 Organic Sales Growth Ex-Covid-19 View to 8.5%-10% >ABT

17. apr 2024, 11:30 UTC

Tulu

Abbott Labs 1Q Organic Sales for Underlying Base Business Rose 10.8% >ABT

17. apr 2024, 11:30 UTC

Tulu

Abbott Raises Midpoint of Full-Year Guidance Ranges >ABT

17. apr 2024, 11:30 UTC

Tulu

Abbott Labs Sees FY Adj EPS $4.55-Adj EPS $4.70 >ABT

17. apr 2024, 11:30 UTC

Tulu

Abbott Labs 1Q Adj EPS 98c >ABT

17. apr 2024, 11:30 UTC

Tulu

Abbott Labs 1Q EPS 70c >ABT

17. apr 2024, 11:30 UTC

Tulu

Abbott Labs Sees FY EPS $3.25-EPS $3.40 >ABT

17. apr 2024, 11:30 UTC

Tulu

Abbott Labs 1Q Net $1.23B >ABT

17. apr 2024, 11:30 UTC

Tulu

Abbott Labs 1Q Organic Sales Growth Up 4.7% >ABT

17. apr 2024, 11:30 UTC

Tulu

Abbott Labs 1Q Sales $9.96B >ABT

Võrdlus sarnastega

Hinnamuutus

Abbott Laboratories Prognoos

Hinnasiht

By TipRanks

26.21% tõus

12 kuu keskmine prognoos

Keskmine 126.3 USD  26.21%

Kõrge 140 USD

Madal 107 USD

Põhineb 10 Wall Streeti analüütiku instrumendi Abbott Laboratories 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Tugev "osta" hinnang

10 ratings

9

Osta

1

Hoia

0

Müü

Tehniline skoor

By Trading Central

101.76 / 104.02Toetus ja vastupanu

Lühikene perspektiiv

Very Strong Bearish Evidence

Keskpikk perspektiiv

Bearish Evidence

Pikk perspektiiv

Strong Bearish Evidence

Sentiment

By Acuity

107 / 369 Pingereas Tervishoid

Uudiste sentiment

Languse märgid

Volatiilsus

Alla keskmise

Uudismaht (RCV)

Üle keskmise

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

$

Ettevõttest Abbott Laboratories

Abbott Laboratories (Abbott) is engaged in the discovery, development, manufacture, and sale of a diversified line of health care products. The Company operates through four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. Its products include a line of rhythm management, electrophysiology, heart failure, vascular and structural heart devices for the treatment of cardiovascular diseases, and diabetes care products for people with diabetes, as well as neuromodulation devices for the management of chronic pain and movement disorders. The Company’s products are sold directly to wholesalers, distributors, government agencies, health care facilities, pharmacies, and independent retailers from Abbott-owned distribution centers and public warehouses. It offers cardiovascular and metabolic products, including Lipanthyl, TriCor, Teveten, Teveten Plus, Physiotens, and Synthroid.